Recommended assessment of brain function
| Brain . | Assessment . | Interval . |
|---|---|---|
| Clinical | MRI and MRA of the brain TCD if <16 years (if expertise available) | Before intervention Then yearly ×2 At 5 years after intervention Repeat every 5 years or earlier as needed in the event of symptoms |
| Cognitive assessment∗ Global measures such as Bayley-III (0-3.5 years), intelligence quotient (WPPSI-IV and WISC-V). Domain-specific measures: executive function working memory, attention, and processing speed | Before intervention Then yearly ×2 At 5 years after intervention Repeat every 5 years or earlier as needed in the event of intervention | |
| Research | Cerebral hemodynamics∗: cerebral blood flow, oxygen extraction fraction, cerebrovascular reactivity, and MR velocity | Before intervention Then yearly ×2 Repeat at 5 years and continue beyond if impaired |
| Brain . | Assessment . | Interval . |
|---|---|---|
| Clinical | MRI and MRA of the brain TCD if <16 years (if expertise available) | Before intervention Then yearly ×2 At 5 years after intervention Repeat every 5 years or earlier as needed in the event of symptoms |
| Cognitive assessment∗ Global measures such as Bayley-III (0-3.5 years), intelligence quotient (WPPSI-IV and WISC-V). Domain-specific measures: executive function working memory, attention, and processing speed | Before intervention Then yearly ×2 At 5 years after intervention Repeat every 5 years or earlier as needed in the event of intervention | |
| Research | Cerebral hemodynamics∗: cerebral blood flow, oxygen extraction fraction, cerebrovascular reactivity, and MR velocity | Before intervention Then yearly ×2 Repeat at 5 years and continue beyond if impaired |
MRI, Magnetic Resonance Imaging; MRA, Magnetic Resonance Angiography; TCD, Transcranial Doppler velocity; WISC-V, Wechsler Intelligence Scale for Children-Fifth edition; WPPSI-IV, Wechsler Preschool and Primary Scale of Intelligence-Fourth edition; MR, Magnetic Resonance.
For specific measures, refer to Tables 5 and 6 in end points for clinical trials in SCD.8